Verastem, Inc. (VSTM) Stock Price

VSTMStock

$7.22−21.78%52W

Market Cap$653.87M

P/E—

PEG Ratio—

Div yield—

Beta0.50

VSTM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)10.44%

Price vs S&P 500 (4W)25.35%

VGM Score52.64

Book Value / Share (Quarterly)$0.93

P/TBV (Annual)14.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.24%

Cash Flow / Share (Quarterly)$-1.83

Price vs S&P 500 (YTD)-19.30%

Gross Margin (TTM)85.13%

Net Profit Margin (TTM)-391.16%

EPS (TTM)$-2.51

10-Day Avg Trading Volume1.73M

EPS Excl Extra (TTM)$-2.51

Revenue Growth (5Y)-18.97%

EPS (Annual)$-3.02

ROI (Annual)-145.64%

Gross Margin (Annual)82.86%

Net Profit Margin (5Y Avg)-1674.50%

Cash / Share (Quarterly)$2.07

ROA (Last FY)-85.00%

Revenue Growth TTM (YoY)209.14%

EBITD / Share (TTM)$-2.12

ROE (5Y Avg)-154.64%

Operating Margin (TTM)-344.56%

Cash Flow / Share (Annual)$-1.89

P/B Ratio7.17x

P/B Ratio (Quarterly)5.69x

Net Income / Employee (Annual)$-2,053,600

EV / Revenue (TTM)10.15x

Net Interest Coverage (TTM)-314.86x

ROA (TTM)-91.56%

EPS Incl Extra (Annual)$-3.02

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)2.88x

3-Month Avg Trading Volume2.40M

52-Week Price Return-21.78%

Revenue / Employee (TTM)$486,100

Tangible BV / Share (Quarterly)$0.75

P/S Ratio (Annual)18.96x

Asset Turnover (Annual)0.13x

52-Week High$11.25

Operating Margin (5Y Avg)-1512.87%

EPS Excl Extra (Annual)$-3.02

CapEx CAGR (5Y)217.14%

Tangible BV CAGR (5Y)-3.85%

26-Week Price Return22.37%

Quick Ratio (Annual)2.96x

13-Week Price Return68.30%

Total Debt / Equity (Annual)1.51x

Current Ratio (Quarterly)3.04x

Enterprise Value$503.23M

Revenue / Share Growth (5Y)-42.22%

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-7.04%

Revenue / Employee (Annual)$303,100

Pretax Margin (Annual)-677.59%

Cash / Share (Annual)$2.64

3-Month Return Std Dev73.51%

Gross Margin (5Y Avg)87.71%

Net Income / Employee (TTM)$-1,901,600

ROE (Last FY)-366.23%

Net Interest Coverage (Annual)-147.60x

EPS Basic Excl Extra (Annual)$-3.02

Receivables Turnover (TTM)0.35x

Total Debt / Equity (Quarterly)1.01x

EPS Incl Extra (TTM)$-2.51

Receivables Turnover (Annual)0.00x

ROI (TTM)-66.90%

P/S Ratio (TTM)11.82x

Pretax Margin (5Y Avg)-1674.08%

Revenue / Share (Annual)$0.45

Tangible BV / Share (Annual)$0.52

Price vs S&P 500 (52W)-40.34%

Year-to-Date Return-6.48%

5-Day Price Return5.25%

EPS Normalized (Annual)$-3.02

ROA (5Y Avg)-83.02%

Net Profit Margin (Annual)-677.59%

Month-to-Date Return24.48%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-2.48

Operating Margin (Annual)-556.24%

LT Debt / Equity (Annual)1.42x

ROI (5Y Avg)-90.60%

LT Debt / Equity (Quarterly)0.94x

EPS Basic Excl Extra (TTM)$-2.51

P/TBV (Quarterly)7.09x

P/B Ratio (Annual)10.17x

Inventory Turnover (TTM)21.26x

Pretax Margin (TTM)-391.16%

Book Value / Share (Annual)$0.74

Price vs S&P 500 (13W)66.34%

Beta0.50x

Revenue / Share (TTM)$0.50

ROE (TTM)-163.59%

52-Week Low$3.43

vGradeD

gGradeC

mGradeB

vgmGradeC

VSTM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.45	-$0.31	+30.60%(+$0.14)
Q1 2026	May 7, 2026	-$0.47	-$0.43	+7.86%(+$0.04)
Q4 2025	Mar 4, 2026	-$0.50	-$0.46	+7.54%(+$0.04)
Q3 2025	Nov 4, 2025	-$0.61	-$0.54	+10.99%(+$0.07)
Q2 2025	Aug 7, 2025	-$0.74	-$0.63	+15.44%(+$0.11)

VSTM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
VSTMVerastem, Inc.	D	C	B	$7.22
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Verastem, Inc.

Verastem Inc is a late-stage development biopharmaceutical company developing novel anticancer agents targeting critical signaling pathways in cancer. The company's pipeline is focused on RAF/MEK and FAK inhibition to suppress cancer cell survival and tumor growth.